Cargando…

CD4(+) T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS

Myasthenia gravis (MG) is an autoimmune disease mediated by autoantibodies predominantly against the acetylcholine receptor (AChR). Specific T cell subsets are required for long-term antibody responses, and cytokines secreted mainly from CD4(+) T cells regulate B cell antibody production. The aim of...

Descripción completa

Detalles Bibliográficos
Autores principales: Çebi, Merve, Durmus, Hacer, Aysal, Fikret, Özkan, Berker, Gül, Gizem Engin, Çakar, Arman, Hocaoglu, Mehmet, Mercan, Metin, Yentür, Sibel P., Tütüncü, Melih, Yayla, Vildan, Akan, Onur, Dogan, Öner, Parman, Yeşim, Saruhan-Direskeneli, Güher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248174/
https://www.ncbi.nlm.nih.gov/pubmed/32508812
http://dx.doi.org/10.3389/fimmu.2020.00809
_version_ 1783538311339442176
author Çebi, Merve
Durmus, Hacer
Aysal, Fikret
Özkan, Berker
Gül, Gizem Engin
Çakar, Arman
Hocaoglu, Mehmet
Mercan, Metin
Yentür, Sibel P.
Tütüncü, Melih
Yayla, Vildan
Akan, Onur
Dogan, Öner
Parman, Yeşim
Saruhan-Direskeneli, Güher
author_facet Çebi, Merve
Durmus, Hacer
Aysal, Fikret
Özkan, Berker
Gül, Gizem Engin
Çakar, Arman
Hocaoglu, Mehmet
Mercan, Metin
Yentür, Sibel P.
Tütüncü, Melih
Yayla, Vildan
Akan, Onur
Dogan, Öner
Parman, Yeşim
Saruhan-Direskeneli, Güher
author_sort Çebi, Merve
collection PubMed
description Myasthenia gravis (MG) is an autoimmune disease mediated by autoantibodies predominantly against the acetylcholine receptor (AChR). Specific T cell subsets are required for long-term antibody responses, and cytokines secreted mainly from CD4(+) T cells regulate B cell antibody production. The aim of this study was to assess the differences in the cytokine expressions of CD4(+) T cells in MG patients with AChR antibodies (AChR-MG) and the effect of immunosuppressive (IS) therapy on cytokine activity and to test these findings also in MG patients without detectable antibodies (SN-MG). Clinically diagnosed AChR-MG and SN-MG patients were included. The AChR-MG patients were grouped as IS-positive and -negative and compared with age- and sex-matched healthy controls. Peripheral blood mononuclear cells were used for ex vivo intracellular cytokine production, and subsets of CD4(+) T cells and circulating follicular helper T (cTfh) cells were detected phenotypically by the expression of the chemokine and the costimulatory receptors. Thymocytes obtained from patients who had thymectomy were also analyzed. IL-21, IL-4, IL-10, and IL-17A productions in CD4(+) T cells were increased in AChR-MG compared to those in healthy controls. IS treatment enhanced IL-10 and reduced IFN-γ production in AChR-MG patients compared to those in IS-negative patients. Increased IL-21 and IL-4 productions were also demonstrated in SN-MG patients. Among CD4(+) T cells, Th17 cells were increased in both disease subgroups. Treatment induced higher proportions of Th2 cells in AChR-MG patients. Both CXCR5(+) and CXCR5(−) CD4(+) T cells expressed higher programmed cell death protein 1 (PD-1) and inducible costimulatory (ICOS) in AChR-MG and SN-MG groups, mostly irrespective of the treatment. Based on chemokine receptors on CXCR5(+)PD-1(+) in CD4(+) T (cTfh) cells, in AChR-MG patients without treatment, the proportions of Tfh17 cells were higher than those in the treated group, whereas the Tfh1 cells were decreased compared with those in the controls. The relevance of CXCR5 and PD-1 in the pathogenesis of AChR-MG was also suggested by the increased presence of these molecules on mature CD4 single-positive thymocytes from the thymic samples. The study provides further evidence for the importance of IL-21, IL-17A, IL-4, and IL-10 in AChR-MG. Disease-related CD4(+)T cells are identified mainly as PD-1(+) or ICOS(+) with or without CXCR5, resembling cTfh cells in the circulation or probably in the thymus. AChR-MG and SN-MG seem to have some similar characteristics. IS treatment has distinctive effects on cytokine expression.
format Online
Article
Text
id pubmed-7248174
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-72481742020-06-05 CD4(+) T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS Çebi, Merve Durmus, Hacer Aysal, Fikret Özkan, Berker Gül, Gizem Engin Çakar, Arman Hocaoglu, Mehmet Mercan, Metin Yentür, Sibel P. Tütüncü, Melih Yayla, Vildan Akan, Onur Dogan, Öner Parman, Yeşim Saruhan-Direskeneli, Güher Front Immunol Immunology Myasthenia gravis (MG) is an autoimmune disease mediated by autoantibodies predominantly against the acetylcholine receptor (AChR). Specific T cell subsets are required for long-term antibody responses, and cytokines secreted mainly from CD4(+) T cells regulate B cell antibody production. The aim of this study was to assess the differences in the cytokine expressions of CD4(+) T cells in MG patients with AChR antibodies (AChR-MG) and the effect of immunosuppressive (IS) therapy on cytokine activity and to test these findings also in MG patients without detectable antibodies (SN-MG). Clinically diagnosed AChR-MG and SN-MG patients were included. The AChR-MG patients were grouped as IS-positive and -negative and compared with age- and sex-matched healthy controls. Peripheral blood mononuclear cells were used for ex vivo intracellular cytokine production, and subsets of CD4(+) T cells and circulating follicular helper T (cTfh) cells were detected phenotypically by the expression of the chemokine and the costimulatory receptors. Thymocytes obtained from patients who had thymectomy were also analyzed. IL-21, IL-4, IL-10, and IL-17A productions in CD4(+) T cells were increased in AChR-MG compared to those in healthy controls. IS treatment enhanced IL-10 and reduced IFN-γ production in AChR-MG patients compared to those in IS-negative patients. Increased IL-21 and IL-4 productions were also demonstrated in SN-MG patients. Among CD4(+) T cells, Th17 cells were increased in both disease subgroups. Treatment induced higher proportions of Th2 cells in AChR-MG patients. Both CXCR5(+) and CXCR5(−) CD4(+) T cells expressed higher programmed cell death protein 1 (PD-1) and inducible costimulatory (ICOS) in AChR-MG and SN-MG groups, mostly irrespective of the treatment. Based on chemokine receptors on CXCR5(+)PD-1(+) in CD4(+) T (cTfh) cells, in AChR-MG patients without treatment, the proportions of Tfh17 cells were higher than those in the treated group, whereas the Tfh1 cells were decreased compared with those in the controls. The relevance of CXCR5 and PD-1 in the pathogenesis of AChR-MG was also suggested by the increased presence of these molecules on mature CD4 single-positive thymocytes from the thymic samples. The study provides further evidence for the importance of IL-21, IL-17A, IL-4, and IL-10 in AChR-MG. Disease-related CD4(+)T cells are identified mainly as PD-1(+) or ICOS(+) with or without CXCR5, resembling cTfh cells in the circulation or probably in the thymus. AChR-MG and SN-MG seem to have some similar characteristics. IS treatment has distinctive effects on cytokine expression. Frontiers Media S.A. 2020-05-19 /pmc/articles/PMC7248174/ /pubmed/32508812 http://dx.doi.org/10.3389/fimmu.2020.00809 Text en Copyright © 2020 Çebi, Durmus, Aysal, Özkan, Gül, Çakar, Hocaoglu, Mercan, Yentür, Tütüncü, Yayla, Akan, Dogan, Parman and Saruhan-Direskeneli. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Çebi, Merve
Durmus, Hacer
Aysal, Fikret
Özkan, Berker
Gül, Gizem Engin
Çakar, Arman
Hocaoglu, Mehmet
Mercan, Metin
Yentür, Sibel P.
Tütüncü, Melih
Yayla, Vildan
Akan, Onur
Dogan, Öner
Parman, Yeşim
Saruhan-Direskeneli, Güher
CD4(+) T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS
title CD4(+) T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS
title_full CD4(+) T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS
title_fullStr CD4(+) T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS
title_full_unstemmed CD4(+) T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS
title_short CD4(+) T Cells of Myasthenia Gravis Patients Are Characterized by Increased IL-21, IL-4, and IL-17A Productions and Higher Presence of PD-1 and ICOS
title_sort cd4(+) t cells of myasthenia gravis patients are characterized by increased il-21, il-4, and il-17a productions and higher presence of pd-1 and icos
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248174/
https://www.ncbi.nlm.nih.gov/pubmed/32508812
http://dx.doi.org/10.3389/fimmu.2020.00809
work_keys_str_mv AT cebimerve cd4tcellsofmyastheniagravispatientsarecharacterizedbyincreasedil21il4andil17aproductionsandhigherpresenceofpd1andicos
AT durmushacer cd4tcellsofmyastheniagravispatientsarecharacterizedbyincreasedil21il4andil17aproductionsandhigherpresenceofpd1andicos
AT aysalfikret cd4tcellsofmyastheniagravispatientsarecharacterizedbyincreasedil21il4andil17aproductionsandhigherpresenceofpd1andicos
AT ozkanberker cd4tcellsofmyastheniagravispatientsarecharacterizedbyincreasedil21il4andil17aproductionsandhigherpresenceofpd1andicos
AT gulgizemengin cd4tcellsofmyastheniagravispatientsarecharacterizedbyincreasedil21il4andil17aproductionsandhigherpresenceofpd1andicos
AT cakararman cd4tcellsofmyastheniagravispatientsarecharacterizedbyincreasedil21il4andil17aproductionsandhigherpresenceofpd1andicos
AT hocaoglumehmet cd4tcellsofmyastheniagravispatientsarecharacterizedbyincreasedil21il4andil17aproductionsandhigherpresenceofpd1andicos
AT mercanmetin cd4tcellsofmyastheniagravispatientsarecharacterizedbyincreasedil21il4andil17aproductionsandhigherpresenceofpd1andicos
AT yentursibelp cd4tcellsofmyastheniagravispatientsarecharacterizedbyincreasedil21il4andil17aproductionsandhigherpresenceofpd1andicos
AT tutuncumelih cd4tcellsofmyastheniagravispatientsarecharacterizedbyincreasedil21il4andil17aproductionsandhigherpresenceofpd1andicos
AT yaylavildan cd4tcellsofmyastheniagravispatientsarecharacterizedbyincreasedil21il4andil17aproductionsandhigherpresenceofpd1andicos
AT akanonur cd4tcellsofmyastheniagravispatientsarecharacterizedbyincreasedil21il4andil17aproductionsandhigherpresenceofpd1andicos
AT doganoner cd4tcellsofmyastheniagravispatientsarecharacterizedbyincreasedil21il4andil17aproductionsandhigherpresenceofpd1andicos
AT parmanyesim cd4tcellsofmyastheniagravispatientsarecharacterizedbyincreasedil21il4andil17aproductionsandhigherpresenceofpd1andicos
AT saruhandireskeneliguher cd4tcellsofmyastheniagravispatientsarecharacterizedbyincreasedil21il4andil17aproductionsandhigherpresenceofpd1andicos